Which proton‑pump inhibitors (PPIs) are considered safe for use in the third trimester of pregnancy, and what are the recommended dosing regimens?

Proton Pump Inhibitors in Third Trimester Pregnancy

Proton pump inhibitors (PPIs) are safe to use during the third trimester of pregnancy, with no evidence of increased risk for congenital malformations, perinatal mortality, or adverse fetal outcomes.

Safety Profile

PPIs can be continued throughout pregnancy, including the third trimester, based on robust evidence from multiple large-scale studies. The most comprehensive data support their use without significant maternal or fetal risk 1, 2, 3, 4.

Evidence for Safety

• No increased malformation risk: A large Israeli cohort study of 1,186 first-trimester exposures found no association with congenital malformations (adjusted OR 1.06; 95% CI 0.84-1.33). Critically, third-trimester exposure showed no increased risk of perinatal mortality, premature delivery, low birth weight, or low Apgar scores 1.

• Meta-analysis confirmation: A 2023 systematic review and meta-analysis of 5,618 exposed pregnancies found no significant increase in overall major congenital malformations (OR 1.10,95% CI 0.95-1.26) or specific malformations 3.

• Sibling-controlled data: A Korean population-based study of 2.7 million pregnancies found that sibling-controlled analyses showed no association between PPI use and major congenital malformations (OR 1.05; 95% CI 0.91-1.22) or congenital heart defects (OR 1.07; 95% CI 0.88-1.30), suggesting familial confounding rather than true teratogenicity 4.

Specific PPIs and Dosing

For gastroesophageal reflux in pregnancy, PPIs are recommended when H2-receptor antagonists fail to control symptoms 5, 6.

Available Options (in order of evidence strength):

• Omeprazole: 20 mg once daily (most studied, extensive safety data) 2, 7
• Lansoprazole: 30 mg once daily 2
• Pantoprazole: 40 mg once daily 2
• Esomeprazole: 20 mg once daily 8
• Rabeprazole: 20 mg once daily 8

All PPIs appear equally safe based on current evidence, though omeprazole has the most extensive pregnancy data 1, 2, 9.

Clinical Considerations

When to Use PPIs in Third Trimester:

1. Persistent gastroesophageal reflux unresponsive to lifestyle modifications and antacids
2. Hyperemesis gravidarum requiring acid suppression 5, 6
3. Continuation of pre-pregnancy PPI therapy for documented indications

Important Caveats:

• Recent FDA database signals: A 2025 analysis of adverse event reports suggested potential associations between omeprazole and postpartum hemorrhage (ROR 3.14) and preeclampsia (ROR 1.95), though these are hypothesis-generating findings from spontaneous reporting systems, not controlled studies 10. These signals require confirmation through rigorous epidemiological studies before changing practice.

• Constipation management: Women on PPIs commonly experience constipation due to reduced food/fluid intake. Offer laxatives proactively, especially if ondansetron is co-prescribed 5.

• Drug interactions: PPIs decrease absorption of drugs requiring acidic pH. Review all concurrent medications, particularly those with narrow therapeutic indices 8.

Practical Algorithm

For third-trimester GERD management:

1. Start with lifestyle modifications (small frequent meals, avoid triggers, elevate head of bed)
2. If inadequate → Add antacids/alginates
3. If inadequate → Add H2-receptor antagonist (ranitidine 150 mg twice daily or famotidine 20 mg twice daily)
4. If inadequate → Initiate PPI therapy (omeprazole 20 mg daily or equivalent)
5. Continue PPI through delivery if needed; no need to discontinue before labor

The evidence strongly supports that PPIs do not need to be discontinued in the third trimester and can be safely continued through delivery and into the postpartum period if clinically indicated 1, 2, 3.